Viridian Therapeutics, Inc. (VRDN) Revenue History
Annual and quarterly revenue from 2012 to present
VRDN Revenue Over Time (2012–2025)
VRDN Revenue Growth History
6 of 13 years with positive growth- FY2012 revenue growth
- N/A
- FY2013 revenue growth
- -2.0%
- FY2014 revenue growth
- +0.1%
- FY2015 revenue growth
- -41.3%
- FY2016 revenue growth
- +31.5%
- FY2017 revenue growth
- +20.0%
- FY2018 revenue growth
- +109.5%
- FY2019 revenue growth
- -46.8%
- FY2020 revenue growth
- -76.5%
- FY2021 revenue growth
- +182.2%
- FY2022 revenue growth
- -40.2%
- FY2023 revenue growth
- -82.3%
- FY2024 revenue growth
- -3.8%
- FY2025 revenue growth
- +23359.9%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $141K | +95.8% |
| Q4 2025 | $132K | +83.3% |
| Q3 2025 | $70.6M | +81958.1% |
| Q2 2025 | $75K | +4.2% |
| Q1 2025 | $72K | +0.0% |
| Q4 2024 | $72K | +0.0% |
| Q3 2024 | $86K | +19.4% |
| Q2 2024 | $72K | +0.0% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
VRDN's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
VRDN Revenue Analysis (2012–2025)
Current Revenue & Growth
As of June 22, 2026, Viridian Therapeutics, Inc. (VRDN) generated trailing twelve-month (TTM) revenue of $70.9 million, reflecting explosive growth of +95.8% year-over-year. The most recent quarter (Q1 2026) recorded $141,000 in revenue, up 6.8% sequentially.
Historical Growth Trajectory
VRDN's 5-year compound annual growth rate (CAGR) stands at +132.2%, indicating outstanding long-term growth trajectory. The 3-year CAGR of +241.9% exceeds the 5-year average, indicating an acceleration in the most recent period. Viridian Therapeutics, Inc.'s highest annual revenue of $70.8 million was recorded in 2025, an all-time high.
Revenue by Segment
VRDN's revenue is primarily driven by License (99%), and Collaboration (1%). With over half of revenue concentrated in License, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including RDVT (+18.1% YoY), KYMR (-12.6% YoY), and AMGN (+9.1% YoY) — VRDN has outperformed the peer group in revenue growth. Compare VRDN vs RDVT →
VRDN Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| VRDNCurrent | $71M | +95.8% | +132.2% | -512.9% | |
 RDVT | $90M | +18.1% | +21.1% | 14.6% | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% | |
 AMGN | $36.7B | +9.1% | +7.6% | 29.1% |
VRDN Historical Revenue Data (2012–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $70.8M | +23359.9% | $70.8M | 100.0% | $-363,395,000 | -512.9% |
| 2024 | $302K | -3.8% | $302K | 100.0% | $-299,035,000 | -99018.2% |
| 2023 | $314K | -82.3% | $314K | 100.0% | $-254,450,000 | -81035.0% |
| 2022 | $1.8M | -40.2% | $1.8M | 100.0% | $-134,304,000 | -7579.2% |
| 2021 | $3.0M | +182.2% | $3.0M | 100.0% | $-79,728,000 | -2690.8% |
| 2020 | $1.1M | -76.5% | $-27,254,000 | -2595.6% | $-110,380,000 | -10512.4% |
| 2019 | $4.5M | -46.8% | $4.5M | 100.0% | $-41,979,000 | -941.0% |
| 2018 | $8.4M | +109.5% | $-22,035,000 | -262.8% | $-33,084,000 | -394.5% |
| 2017 | $4.0M | +20.0% | $-15,620,000 | -390.2% | $-26,532,000 | -662.8% |
| 2016 | $3.3M | +31.5% | $789K | 23.6% | $-12,508,000 | -374.8% |
| 2015 | $2.5M | -41.3% | $66K | 2.6% | $-11,187,000 | -440.8% |
| 2014 | $4.3M | +0.1% | $1.1M | 24.9% | $-6,867,000 | -159.0% |
| 2013 | $4.3M | -2.0% | $1.8M | 42.1% | $-196,213 | -4.5% |
| 2012 | $4.4M | - | $1.4M | 31.0% | $-4,027,000 | -91.4% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
14+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
VRDN — Frequently Asked Questions
Quick answers to the most common questions about buying VRDN stock.
Is VRDN's revenue growth accelerating or slowing?
VRDN revenue growth is accelerating. TTM revenue reached $71M, up +95.8% year-over-year — ahead of the 5-year CAGR of +132.2%. This indicates the business is expanding faster than its historical baseline.
What is VRDN's revenue history from 2012 to 2026?
Viridian Therapeutics, Inc. (VRDN) revenue history spans 2012 to 2026. TTM revenue as of 2026 is $71M, growing at +95.8% YoY. The 5-year CAGR is +132.2%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is VRDN's long-term revenue growth rate (CAGR)?
Viridian Therapeutics, Inc.'s 5-year revenue CAGR of +132.2% reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +95.8% is above this long-term average. CAGR is the most reliable measure of sustained revenue momentum for VRDN.
Why does VRDN's quarterly revenue fluctuate?
VRDN quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Viridian Therapeutics, Inc.'s revenue data from 2012 to 2026 shows full historical quarterly detail on this page.
How is VRDN's revenue distributed by segment?
VRDN reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does VRDN's revenue compare to industry peers?
Viridian Therapeutics, Inc. (VRDN) with TTM revenue of $71M and +95.8% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.